Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2
Abstract
Background and aim. In patients with chronic hepatitis C receiving Peg interferon/ribavirin (PEG-IFN/RBV) who do not achieve ≥ 2log-reduction in HCV-RNA at week 12 (null responders, NR) and in those with ≥ 2log-decrease but detectable at week 24 (partial responders, PR) the probability to achieve the sustained virological response (SVR) is almost null. The aim of this study was to investigate the efficacy of individualized schedule of progressively increased RBV doses in the setting of PEG-IFN/RBV treatment. Material and methods. PR or NR to PEG-IFN/RBV instead of discontinuing treatment were enrolled to receive increasing doses of RBV until a target theoretical concentration ([tRBV]) of ≥ 15 μmol/L (by pharmacokinetic formula based on glomerular filtration rate). HCV-RNA was assessed every 4 weeks and, if detectable, RBV dose was gradually increased until negativization. Twelve weeks later, patients with detectable HCV-RNA discontinued therapy while those with undetectable HCV-RNA continued for further 48 weeks. Results. Twenty genotype-1 patients (8 NR and 12 PR) were enrolled. After 12 weeks 9 (45%) were still HCV-RNA positive and were discontinued, while remaining 11 had undetectable HCV-RNA. One stopped treatment for side effects. Ten completed treatment. Five (all PR) achieved SVR. Side effects incidence was similar to that observed during PEG-IFN/RBV. Conclusions. In conclusion, RBV high doses, according to individualized schedule, increase SVR in PR on a similar extent to that of triple therapy but without increase of side effects. Such treatment should be considered in PR with no access or intolerant to protease inhibitors (PI).
Authors and Affiliations
Fabio Conti, Ranka Vukotic, Stefania Lorenzini, Anna Riili, Carmela Cursaro, Alessandra Scuteri, Elisabetta Loggi, Silvia Galli, Giuliano Furlini, Mauro Bernardi, Pietro Andreone
Keywords
Related Articles
- EP ID EP78375
- DOI -
- Views 93
- Downloads 0
Undifferentiated embryonal sarcoma of liver in an adult masquerading as complicated hydatid cyst
Benign or malignant hepatic lesions may rarely mimic inflammatory lesions on imaging. We describe a case of young adult male presenting with pain abdomen and fever of short duration. Imaging revealed large complex multis...
Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?
Multiple genetic and environmental factors interact to determine an individual’s predisposition to non-alcoholic fatty liver disease and its phenotypic characteristics. Association studies have found a number of alleles...
MicroRNA-146b regulates hepatic stellate cell activation via targeting of KLF4
Background. We previously identified miR-146b as being up-regulated during the development of hepatic fibrosis using deep sequencing technology and gene expression analysis. However, the roles and related mechanisms of...
Spondias pinnata stem bark extract lessens iron overloaded liver toxicity due to hemosiderosis in Swiss albino mice
The present study was designed to evaluate the ameliorating effect of 70% methanol extract of Spondias pinnata (SPME) on iron overload induced liver injury. Iron overload was induced by intraperitoneal administration of...
Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables
Background & aim. This study assessed the involvement of metabolic factors (anthropometric indices, insulin resistance (IR) and adipocytokines) in the prediction of portal hypertension, esophageal varices and...